If there is a dental AI company that has most aggressively pursued the provider market — and specifically the DSO segment — it is Pearl. Based in Los Angeles, Pearl has positioned itself as the go-to AI platform for dental practices seeking real-time diagnostic assistance and practice analytics. With FDA-cleared products deployed across thousands of dental offices, partnerships with some of the largest DSOs in the country, and a product suite that extends well beyond basic radiograph analysis, Pearl has become a defining company in the dental AI landscape.
Company Background and Leadership
Pearl was founded in 2019 by Ophir Tanz, a serial entrepreneur who previously founded GumGum, a computer vision and contextual intelligence company. Tanz brought his expertise in applying computer vision to large-scale commercial problems into the dental space, recognizing that dental radiographs represented one of the largest untapped image datasets in healthcare. Under his leadership as CEO, Pearl has grown from a startup into one of the most widely deployed dental AI platforms in the United States.
The company has assembled a leadership team that combines dental clinical expertise with deep technology and business development backgrounds. Pearl’s clinical advisory board includes practicing dentists and dental specialists who inform the product development process — a factor that has contributed to the platform’s usability and clinical relevance.
Product Suite: Second Opinion and Practice Intelligence
Second Opinion: Real-Time Diagnostic AI
Pearl’s flagship clinical product is Second Opinion, an FDA-cleared AI system that analyzes dental radiographs in real time as they are captured in the operatory. The software automatically detects and annotates a wide range of dental conditions and features, including caries, periapical lesions, calculus, bone loss, existing restorations, crowns, and other findings. The annotations appear as color-coded overlays on the X-ray image, giving both the dentist and the patient a clear visual representation of the AI’s findings.
Second Opinion is designed as a clinical decision support tool — it assists but does not replace the dentist’s judgment. However, its real-time nature makes it particularly useful for patient communication and case acceptance. Multiple DSOs have reported that using Pearl’s visual overlays during patient consultations significantly improves patient understanding of recommended treatment, which in turn drives higher case acceptance rates.
The product integrates with widely used imaging systems and practice management software, and Pearl has invested significantly in making the deployment process as frictionless as possible — an important consideration for DSOs rolling out technology across hundreds of locations simultaneously.
Practice Intelligence: Analytics Beyond the Operatory
Pearl’s second major product line is Practice Intelligence, an analytics platform that aggregates diagnostic data across a dental organization to provide insights into clinical patterns, treatment trends, and quality metrics. For DSO leadership, Practice Intelligence offers a data-driven view into how individual practices and providers are performing relative to peers and organizational benchmarks.
The platform can surface insights such as undiagnosed conditions in patient populations, variation in diagnostic patterns across providers, and opportunities for improved patient care. This positions Practice Intelligence as both a quality assurance tool and a business intelligence tool — helping DSOs identify clinical improvement opportunities that also happen to have revenue implications.
Pearl’s combination of chairside diagnostic AI and enterprise-level practice analytics represents a full-stack approach to dental AI that few competitors have matched. The ability to capture data at the point of care and roll it up into organizational intelligence is a powerful value proposition for DSOs managing dozens or hundreds of locations.
FDA Clearances
Pearl has secured FDA 510(k) clearance for Second Opinion, making it one of the first dental AI platforms to receive formal regulatory authorization for clinical use. The company’s FDA clearance covers detection of multiple dental conditions from radiographic images. Pearl has publicly emphasized its FDA-cleared status as a key differentiator, and it is a factor that has been significant in winning DSO contracts where compliance and regulatory standing are evaluated during vendor selection.
The company has reported that its AI algorithms were trained on millions of dental images with annotations provided by dental professionals, and that its clinical validation studies have demonstrated performance comparable to or exceeding that of general dentists for specific detection tasks.
DSO Deployments and Scale
Pearl has secured several landmark DSO partnerships that underscore its reach in the organized dentistry market. PDS Health (formerly Pacific Dental Services), one of the largest dental support organizations in the United States with over 900 supported offices, deployed Pearl’s technology across its network — a deal that represented one of the largest AI rollouts in dental history. Coast Dental, another significant DSO, has also adopted Pearl’s platform.
These large-scale deployments have given Pearl a significant installed base and, critically, an enormous volume of real-world usage data that feeds back into model improvement. The company has reported that its AI has been used to analyze over 100 million dental images — a scale claim that, if accurate, would place it among the most widely used dental AI platforms globally.
- PDS Health: Enterprise-wide deployment across 900+ supported offices
- Coast Dental: Multi-location deployment of Second Opinion platform
- Thousands of Individual Practices: Growing adoption among independent dentists and smaller groups
Funding and Growth
Pearl has raised significant venture capital to fuel its growth. The company completed a $58 million Series B funding round in 2023, led by Left Lane Capital. This followed earlier rounds that brought the company’s total funding to over $80 million. The investment has supported Pearl’s aggressive DSO sales strategy, product development for Practice Intelligence, expansion of its engineering and clinical teams, and growing international ambitions.
The funding positions Pearl among the best-capitalized dental AI companies, alongside Overjet and VideaHealth. This level of investment suggests that Pearl’s backers see a large addressable market and believe the company can capture a significant share of it — but it also means Pearl will need to demonstrate strong revenue growth to justify its valuation over time.
Competitive Position: Strengths and Limitations
Pearl’s core strength lies in its laser focus on the provider side of the market and its demonstrated ability to deploy at DSO scale. The combination of chairside AI (Second Opinion) and enterprise analytics (Practice Intelligence) gives DSOs a more comprehensive platform than point solutions that only address diagnostic assistance. The company’s track record with major DSOs like PDS Health provides powerful social proof for other organizations evaluating dental AI.
That said, DSOs considering Pearl should weigh several factors. First, the dental AI market is becoming increasingly competitive, with companies like Overjet, VideaHealth, and others offering similar diagnostic capabilities. Differentiation increasingly hinges not just on detection accuracy but on integration depth, analytics, support quality, and pricing. Second, while Pearl’s Practice Intelligence platform is a strong differentiator, some DSOs may already have business intelligence tools in place and may need to evaluate how Pearl’s analytics complement or overlap with existing systems.
Third, unlike Overjet, Pearl does not have a significant presence on the insurance side of the market. Whether this is a strength (undivided focus on providers) or a limitation (missing a major revenue stream and data source) depends on one’s perspective. Some DSO leaders may prefer a vendor that is exclusively aligned with the provider side, free from potential conflicts of interest inherent in serving insurers simultaneously.
Looking Forward
Pearl enters the next phase of dental AI’s evolution from a position of strength. Its installed base across major DSOs, its FDA-cleared diagnostic platform, and its expanding Practice Intelligence analytics suite give it multiple vectors for growth. The company has signaled interest in international expansion and in broadening the range of clinical conditions its AI can detect.
For DSOs evaluating Pearl, the company presents a mature, well-funded, and widely deployed option with a clear focus on the provider market. The depth of its DSO relationships and its dual product strategy — combining real-time clinical AI with organizational analytics — make it a vendor worth serious consideration in any dental AI evaluation process. As with any technology investment, DSOs should assess integration requirements, pricing models, clinical validation data, and reference customers before making a commitment.
dsonews.ai is an independent publication. This vendor profile is provided for informational purposes and does not constitute an endorsement. DSOs should conduct their own due diligence before selecting any technology vendor.
Leave a Reply